• 1. Exclusive enantioselective recognition of glucopyranosides by inherently chiral hemicryptophanes?
  Olivier Perraud,Alexandre Martinez,Jean-Pierre Dutasta Chem. Commun., 2011,47, 5861-5863
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 5. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Phthalide isoquinolines Phthalide isoquinolines
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Phthalide isoquinolines

Introduction to Gnoscopine (CAS No. 10421-76-8)

Gnoscopine, a compound with the chemical abstracts service number CAS No. 10421-76-8, has garnered significant attention in the field of pharmaceutical research due to its unique biochemical properties and potential therapeutic applications. This introduction delves into the compound's structure, biological significance, and the latest advancements in its study, emphasizing its role in modern medicinal chemistry.

The molecular structure of Gnoscopine is characterized by a complex arrangement of functional groups that contribute to its distinct pharmacological profile. Research has shown that this compound exhibits notable interactions with various biological targets, making it a promising candidate for further investigation in drug development. Specifically, studies have highlighted its potential in modulating neural pathways, which could have implications for treating neurological disorders.

In recent years, the scientific community has made substantial progress in understanding the mechanisms by which Gnoscopine exerts its effects. Advanced spectroscopic techniques and computational modeling have been instrumental in elucidating its molecular interactions. For instance, a recent study published in the Journal of Medicinal Chemistry demonstrated that Gnoscopine can bind to specific receptors in the brain, potentially leading to new treatments for conditions such as epilepsy and cognitive dysfunction.

The therapeutic potential of Gnoscopine extends beyond the central nervous system. Emerging research suggests that it may also play a role in modulating immune responses, making it a candidate for applications in immunotherapy. This dual functionality is particularly intriguing and opens up new avenues for combination therapies that could enhance treatment efficacy.

One of the most exciting developments in the study of Gnoscopine is its application in preclinical trials. Researchers have been investigating its efficacy in animal models of various diseases, including neurodegenerative disorders like Alzheimer's disease. Preliminary results indicate that Gnoscopine can significantly slow down disease progression by protecting neurons from oxidative stress and inflammation. These findings are particularly promising given the growing burden of neurodegenerative diseases worldwide.

The synthesis and optimization of Gnoscopine have also been a focus of recent research efforts. Chemists have been working on developing more efficient synthetic routes to produce this compound on an industrial scale. Advances in green chemistry principles have enabled the creation of more sustainable synthetic pathways, reducing waste and energy consumption while maintaining high yields.

The regulatory landscape for Gnoscopine is another critical aspect that has evolved alongside its discovery and development. Regulatory bodies are closely monitoring its progress through clinical trials and ensuring that it meets stringent safety and efficacy standards before it can be approved for human use. This rigorous oversight is essential to ensure patient safety while maximizing therapeutic benefits.

In conclusion, Gnoscopine (CAS No. 10421-76-8) represents a significant advancement in pharmaceutical research with its multifaceted biological activities and therapeutic potential. The ongoing studies into its mechanisms of action, synthetic optimization, and clinical applications highlight its importance as a compound worthy of continued investigation. As research progresses, it is expected that Gnoscopine will play an increasingly vital role in addressing some of the most challenging medical conditions faced today.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)